Salvage Using Polatuzumab Vedotin Based Therapy in Relapsed Refractory Large B-Cell Lymphomas: Early Experience from a Real-World Middle-Income Setting Using Named-Patient Compassionate Access Program

Polatuzumab vedotin is a novel immunotherapy antibody–drug conjugate targeting CD79b. It has been used in relapsed/refractory (R/R) large B-cell lymphomas since its FDA approval in 2019. Presently, this drug is unaffordable or unavailable for patients in Lower–Middle Income Countries (LMIC) like Ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Radhakrishnan, V. S., Pincha, R., Raina, V., Garg, J. K., Nag, A., Bhave, S. J., Achari, R., Dey, D., Arun, I., Lateef, Z., Vinarkar, S. S., Parihar, M., Sen, S., Mishra, D. K., Chandy, M., Nair, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790077/
https://www.ncbi.nlm.nih.gov/pubmed/36590655
http://dx.doi.org/10.1007/s12288-022-01619-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790077/
https://www.ncbi.nlm.nih.gov/pubmed/36590655
http://dx.doi.org/10.1007/s12288-022-01619-w

Ejemplares similares